Literature DB >> 12211138

MAO-B inhibitors for the treatment of Parkinson's disease.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12211138     DOI： 10.1002/mds.5559

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  5 in total

1.  Using monoamine oxidase type B inhibitors in Parkinson's disease.

Authors:  Yoav Ben-Shlomo; Kailash Bhatia
Journal:  BMJ       Date:  2004-09-11

Review 2.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

3.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.

Authors:  Natalie J Ives; Rebecca L Stowe; Joanna Marro; Carl Counsell; Angus Macleod; Carl E Clarke; Richard Gray; Keith Wheatley
Journal:  BMJ       Date:  2004-08-13

Review 4.  Rasagiline: a review of its use in the management of Parkinson's disease.

Authors:  Vicki Oldfield; Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Authors:  Maroof Husain; Rakesh Shukla; Madhu Dikshit; Pradeep K Maheshwari; Devika Nag; Rikhab C Srimal; Prahlad K Seth; Vinay K Khanna
Journal:  Neurochem Res       Date:  2009-03-04       Impact factor: 3.996
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.